|
It's being called the largest research fraud in medical history. Dr. Scott Reuben, a former member of Pfizer's speakers' bureau, has agreed to plead guilty to faking dozens of research studies that were published in medical journals. Now being reported across the mainstream media is the fact that Dr. Reuben accepted a $75,000 grant from Pfizer to study Celebrex in 2005. His research, which was published in a medical journal, has since been quoted by hundreds of other doctors and researchers as "proof" that Celebrex helped reduce pain during post-surgical recovery. There's only one problem with all this: No patients were ever enrolled in the study!
|
|
|
|
The Food and Drug Administration has reversed its position on the safety of Bisphenol A, a chemical found in plastic bottles, soda cans, food containers and thousands of consumer goods, saying it now has concerns about health risks.
Growing scientific evidence has linked the chemical to a host of problems, including cancer, sexual dysfunction and heart disease. Federal officials said they are particularly concerned about BPA's effect on the development of fetuses, infants and young children.
|
|
|
Researchers investigating our sleep mechanisms have recently determined that periods of lost sleep cannot be made up for at a later date. In a sense, the damage that is done when you force yourself to remain awake for tens of hours continuously cannot be made up for if you sleep 20 hours or more after that. The team has also underlined that the ill-effects of sleep deprivation during the week cannot be undone by sleeping more in the weekend, LiveScience reports.
|
|
| Barred from using lead, Chinese makers using more dangerous cadmium
This Rudolph charm, sold at a Dollar N More store, consisted of up to 90 percent cadmium, lab tests found.
Barred from using lead in children's jewelry because of its toxicity, some Chinese manufacturers have been substituting the more dangerous heavy metal cadmium in sparkling charm bracelets and shiny pendants being sold throughout the United States, an Associated Press investigation shows.
|
|
|
Merck was in trouble. In 2002, the pharmaceutical giant was falling behind its rivals in sales. Even worse, patents on five blockbuster drugs were about to expire, which would allow cheaper generics to flood the market. The company hadn't introduced a truly new product in three years, and its stock price was plummeting.
In interviews with the press, Edward Scolnick, Merck's research director, laid out his battle plan to restore the firm to preeminence. Key to his strategy was expanding the company's reach into the antidepressant market, where Merck had lagged while competitors like Pfizer and GlaxoSmithKline created some of the best-selling drugs in the world. "To remain dominant in the future," he told Forbes, "we need to dominate the central nervous system."
|
|
|
|
|
|
|
|
Page 1 of 13 |